- ALT5 Sigma (ALTS, Financial) is now part of three prestigious Russell indexes, enhancing its market visibility.
- The company has processed over $5 billion in cryptocurrency transactions since its inception in 2018.
- ALT5’s biotech division, Alyea Therapeutics, develops JAN123, a CRPS treatment with FDA Orphan Drug Designation.
ALT5 Sigma Corporation (ALTS), a leading fintech provider of blockchain-based payment and trading infrastructure, has announced its inclusion in three notable Russell indexes: the Russell Microcap Growth®, Russell 3000E®, and Russell 3000E Growth® as part of the 2025 Russell indexes reconstitution. Previously, the company was a member of the Russell Microcap® Index since June 2024.
The inclusion in the broader Russell 3000E® Index, which encompasses approximately 99% of the investable US equity market, marks a significant milestone for ALT5 Sigma. Their entry into these indexes not only highlights increased market recognition but also enhances the company's visibility among institutional investors.
Founded in 2018, ALT5 Sigma has demonstrated significant growth, having processed over $5 billion USD in cryptocurrency transactions and supporting over 1,000 businesses globally through its two primary platforms: ALT5 Pay and ALT5 Prime. ALT5 Pay facilitates cryptocurrency payment gateways for merchants, while ALT5 Prime offers an over-the-counter trading platform for digital assets.
Additionally, ALT5 Sigma is progressing the separation of its biotech division under Alyea Therapeutics Corporation. The division is focused on developing JAN123, a novel low-dose naltrexone formulation for Complex Regional Pain Syndrome (CRPS), which holds an FDA Orphan Drug Designation.
ALT5's CEO, Peter Tassiopoulos, emphasized that the inclusion in these indices validates the company's strategic vision and execution capabilities, and sees it as a catalyst for increased visibility and potential institutional interest.
